Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats.
This experiment was designed to investigate the effect of converting enzyme inhibition on functional and structural vascular alterations in one-kidney, one clip hypertensive rats and in normotensive rats. Starting 1 day before surgery, 100 mg/kg/day captopril was given chronically to half of the hypertensive and normotensive groups in their drinking water. With use of intravital microscopy in the cremaster muscle, arteriolar dimensions were measured 4 weeks later, both before and after topical application of 10(-3) M adenosine. Mean blood pressure was 124 +/- 4 mm Hg in control rats and 103 +/- 5 mm Hg in captopril-treated control rats (p less than 0.05). Mean blood pressure was significantly elevated to 183 +/- 5 mm Hg in captopril-treated one-kidney, one clip hypertensive rats and 193 +/- 5 mm Hg in one-kidney, one clip hypertensive rats. With use of histological techniques, a marked reduction of medial-intimal area of the abdominal aorta was found in captopril-treated control rats (24%), and hypertrophy of the aortic wall in one-kidney, one clip hypertensive rats was decreased 26% by captopril. Structural diameter reductions occurred in large arterioles of the captopril-treated control and hypertensive groups and the nontreated hypertensive group. In spite of a significant increase in wall-to-lumen ratio of first-order arterioles in all captopril-treated rats, captopril decreased cross-sectional wall area of these vessels 37% in hypertensive and 20% in control rats, respectively. Measured by stereological techniques, small arteriolar density decreased 30% in captopril-treated hypertensive rats and 17% in captopril-treated control rats. Therefore, smaller arteriolar lumens, decreased aortic and arteriolar cross-sectional wall area, and arteriolar rarefaction after converting enzyme inhibition, in spite of rising or falling blood pressure, are evidence that vascular growth was inhibited in vivo.
Department of Physiology, Eastern Virginia Medical School, Norfolk 23501.
D H
DH
Wang
R L
RL
Prewitt
D000241:Adenosine / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000254:growth & development* / Q000473:pathology; D001012:Aorta, Abdominal / Q000473:pathology; D001158:Arteries / Q000473:pathology / Q000503:physiopathology; D001160:Arterioles / Q000254:growth & development / Q000473:pathology / Q000503:physiopathology; D002216:Captopril / Q000494:pharmacology*; D008297:Male; D008833:Microcirculation / Q000187:drug effects*; D051381:Rats; D011919:Rats, Inbred Strains; D012044:Regression Analysis; D014666:Vasomotor System / Q000503:physiopathology
D002216:Captopril; D000241:Adenosine